Regulatory
Regulatory | 19 March 2024

Carbogen Amcis (Shanghai) completed ANVISA Audit

A five-day inspection was concluded successfully with no critical and no major observations raised

Regulatory
Regulatory | 19 March 2024

Sun Pharmaceuticals receives approval for Winlevi in Australia

Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older

Regulatory
Regulatory | 18 March 2024

Zydus receives USFDA approval for Finasteride and Tadalafil capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India

Regulatory
Regulatory | 16 March 2024

Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility

The company is confident of addressing the concern raised by the USFDA

Regulatory
Regulatory | 14 March 2024

Zydus receives USFDA final approval for chlorpromazine hydrochloride injection

Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders

Regulatory
Regulatory | 13 March 2024

European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease

PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally

Regulatory
Regulatory | 12 March 2024

USFDA grants orphan drug and pediatric exclusivities for Cresemba for aspergillosis and mucormycosis in children

CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications

Regulatory
Regulatory | 09 March 2024

Venus Remedies obtains marketing authorizations for essential oncology drugs in Ukraine

These approvals mark significant progress for Venus Remedies in expanding its market presence

Regulatory
Regulatory | 09 March 2024

Dishman Carbogen Amcis updates on USFDA inspection at its Bavla facility

The inspection was concluded with few procedural observations

Regulatory
Regulatory | 09 March 2024

USFDA conducts inspection at Alembic Pharmaceuticals' Panelav oncology formulation facility

The company will provide comprehensive response to USFDA for the observations

Regulatory
Regulatory | 07 March 2024

EMA validates MAAs for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in two types of cancer

The validations confirm the completion of the applications and commence the scientific review process

Regulatory
Regulatory | 07 March 2024

Sakar's oncology unit receives EU GMP approval

The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters

Regulatory
Regulatory | 06 March 2024

Strides receives USFDA approval for Gabapentin Tablets

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty

Regulatory
Regulatory | 02 March 2024

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently

Regulatory
Regulatory | 02 March 2024

Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg

The product will be launched in March 2024

Regulatory
Regulatory | 01 March 2024

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

Regulatory
Regulatory | 26 February 2024

Concord Biotech receives GMP certificate from Kenya regulator

The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series

Regulatory
Regulatory | 26 February 2024

Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility

The observations do not pose any risk to site's compliance standards or its business continuity

Regulatory
Regulatory | 26 February 2024

Zydus receives WHO prequalification for Miltefosine formulation and API

Leishmaniasis is caused by protozoan parasites which are transmitted by the bite of infected female phlebotomine sandflies

Regulatory
Regulatory | 24 February 2024

Orchid Pharma's 'Exblifep' receives USFDA approval

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA

Startup

Digitization